STERIS plc (Ireland) Ordinary Shares (STE): Price and Financial Metrics
STERIS plc (Ireland) Ordinary Shares (STE)
Today's Latest Price: $188.76 USD
Updated Jan 22 7:00pm
Add STE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 186 in Medical - Devices & Equipment
See all "A" rated Strong Buy stocks
STE Stock Summary
- STE has a market capitalization of $16,105,759,373 -- more than approximately 87.11% of US stocks.
- STE's went public 5.23 years ago, making it older than just 17.99% of listed US stocks we're tracking.
- The volatility of STERIS plc's share price is greater than that of merely 19.59% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to STERIS plc are SNN, COO, TFX, BRO, and PNR.
- STE's SEC filings can be seen here. And to visit STERIS plc's official web site, go to www.steris.com.
STE Stock Price Chart Interactive Chart >
STE Price/Volume Stats
| Current price | $188.76 | 52-week high | $203.90 |
| Prev. close | $188.33 | 52-week low | $105.69 |
| Day low | $187.06 | Volume | 402,300 |
| Day high | $189.54 | Avg. volume | 499,593 |
| 50-day MA | $190.09 | Dividend yield | 0.85% |
| 200-day MA | $168.76 | Market Cap | 16.11B |
STERIS plc (Ireland) Ordinary Shares (STE) Company Bio
Steris Corporation develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and procedural support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The company was founded in 1985 and is based in Mentor, Ohio.
STE Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $188.76 | $126.01 | -33% |
Below please find a table outlining a discounted cash flow forecast for STE, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that STERIS plc ranked in the 42th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of STERIS plc, consider:
- The company's debt burden, as measured by earnings divided by interest payments, is 14.92; that's higher than 75.77% of US stocks in the Healthcare sector that have positive free cash flow.
- The business' balance sheet suggests that 7% of the company's capital is sourced from debt; this is greater than merely 20.6% of the free cash flow producing stocks we're observing.
- STE's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 3%; for context, that number is higher than 40.11% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -34% |
| 1% | -34% |
| 2% | -33% |
| 3% | -32% |
| 4% | -32% |
| 5% | -31% |
Want more companies with a valuation profile/forecast similar to that of STERIS plc? See QDEL, AMGN, NVS, ADUS, and MEDP.
Loading social stream, please wait...